SVE.WA Stock - Synthaverse S.A.
Unlock GoAI Insights for SVE.WA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $71.76M | $58.61M | $50.38M | $41.15M | $40.16M |
| Gross Profit | $44.25M | $35.17M | $28.47M | $22.67M | $20.57M |
| Gross Margin | 61.7% | 60.0% | 56.5% | 55.1% | 51.2% |
| Operating Income | $12.43M | $8.65M | $9.84M | $7.19M | $5.93M |
| Net Income | $7.55M | $4.76M | $6.08M | $4.25M | $4.44M |
| Net Margin | 10.5% | 8.1% | 12.1% | 10.3% | 11.1% |
| EPS | $0.11 | $0.07 | $0.09 | $0.07 | $0.07 |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.
Visit WebsiteEarnings History & Surprises
SVE.WAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 28, 2025 | — | $-0.11 | — | — |
Q2 2025 | May 29, 2025 | — | $-0.01 | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q4 2024 | Nov 20, 2024 | — | $-0.01 | — | — |
Q3 2024 | Sep 26, 2024 | — | $0.02 | — | — |
Q2 2024 | Apr 10, 2024 | — | $-0.01 | — | — |
Q4 2023 | Dec 31, 2023 | — | $0.06 | — | — |
Q4 2023 | Nov 23, 2023 | — | $-0.03 | — | — |
Q3 2023 | Sep 21, 2023 | — | $0.04 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.01 | — | — |
Q4 2022 | Dec 31, 2022 | $0.02 | $0.04 | +58.5% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | — | $0.02 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.04 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.05 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.05 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.02 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.06 | — | — |
Q3 2020 | Sep 30, 2020 | — | $0.00 | — | — |
Latest News
Frequently Asked Questions about SVE.WA
What is SVE.WA's current stock price?
What is the analyst price target for SVE.WA?
What sector is Synthaverse S.A. in?
What is SVE.WA's market cap?
Does SVE.WA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SVE.WA for comparison